

BMS-265246

Catalog No: tcsc0922



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

582315-72-8

Formula:

$C_{18}H_{17}F_2N_3O_2$

Pathway:

Cell Cycle/DNA Damage

Target:

CDK

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

345.34

Product Description


BMS-265246 is a potent and selective CDK1/2 inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively.

IC50 Value: 6 nM(for CDK1/cyclin B); 9 nM(for CDK2/cyclin E)

Target: CDK1/2

in vitro: BMS-265246 inhibits the activity of Cdk4/cycD (IC₅₀ = 0.23 μM) and prevents A2780 Cytotoxicity with IC₅₀ of 0.76 μM. BMS-265246 when bound to Cdk2, shows the inhibitor resides within the ATP purine binding site and forms important H-bonds with Leu83 on the protein backbone. BMS-265246 represents the most potent Cdk/Cdk2 selective analogue from this chemotype. A recent study shows that BMS-265246 inhibits cell proliferation with EC₅₀ ranging from 0.293 μM-0.492 μM in HCT-116 cells. After treatment of BMS-265246, the dominant cell populations are G₂-arrested cells having 4N DNA content, large round nuclei, and low DNA intensity.

in vivo:



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!